EP2480579A4 - Methods of treating inflammation - Google Patents

Methods of treating inflammation

Info

Publication number
EP2480579A4
EP2480579A4 EP10819481.2A EP10819481A EP2480579A4 EP 2480579 A4 EP2480579 A4 EP 2480579A4 EP 10819481 A EP10819481 A EP 10819481A EP 2480579 A4 EP2480579 A4 EP 2480579A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating inflammation
inflammation
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10819481.2A
Other languages
German (de)
French (fr)
Other versions
EP2480579A2 (en
Inventor
Jurgen Bernhagen
Christian Weber
Benedikt Vollrath
Court Turner
Joshua Robert Schultz
Alma Zernecke
Sergio Duron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carolus Therapeutics Inc
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Publication of EP2480579A2 publication Critical patent/EP2480579A2/en
Publication of EP2480579A4 publication Critical patent/EP2480579A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10819481.2A 2009-09-23 2010-09-23 Methods of treating inflammation Withdrawn EP2480579A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24521409P 2009-09-23 2009-09-23
US31903910P 2010-03-30 2010-03-30
PCT/US2010/050047 WO2011038149A2 (en) 2009-09-23 2010-09-23 Methods of treating inflammation

Publications (2)

Publication Number Publication Date
EP2480579A2 EP2480579A2 (en) 2012-08-01
EP2480579A4 true EP2480579A4 (en) 2013-07-31

Family

ID=43796491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10819481.2A Withdrawn EP2480579A4 (en) 2009-09-23 2010-09-23 Methods of treating inflammation

Country Status (9)

Country Link
EP (1) EP2480579A4 (en)
KR (1) KR20120105429A (en)
CN (1) CN102725311A (en)
AU (1) AU2010298249A1 (en)
BR (1) BR112012006468A2 (en)
CA (1) CA2773978A1 (en)
IN (1) IN2012DN02423A (en)
MX (1) MX2012003514A (en)
WO (1) WO2011038149A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
AU2013262397B2 (en) * 2012-05-17 2017-07-27 Anji Pharmaceuticals Inc. Methods and uses for proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors
TW201605886A (en) * 2013-11-14 2016-02-16 巴克斯特保健公司 MIF as therapeutic target
AU2017231832B2 (en) 2016-03-11 2021-11-11 Ardea Biosciences, Inc. CXCR-2 inhibitors for treating crystal arthropathy disorders
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
AU2019417313B2 (en) * 2018-12-26 2023-01-19 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
WO2021181398A1 (en) * 2020-03-11 2021-09-16 Biolinerx Ltd. Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
US20210338626A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN112656934A (en) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 Application of polypeptide AT03 in medicine for treating primary biliary cholangitis
EP4378319A1 (en) * 2022-12-01 2024-06-05 Bioiberica, S.A.U. Composition comprising bioactive peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
WO2003072753A2 (en) * 2002-02-27 2003-09-04 Emory University Multimeric binding complexes
CN102174108B (en) * 2002-03-01 2016-06-29 免疫医疗公司 The anti-CD74 antibody of internalization and using method
WO2005065328A2 (en) * 2003-12-30 2005-07-21 The United States Of America, As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN102046199A (en) * 2008-03-20 2011-05-04 卡罗勒斯治疗公司 Methods of treatment using anti-mif antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FILIP ANA-MARIA ET AL: "Ribosomal protein S19 interacts with macrophage migration inhibitory factor and attenuates its pro-inflammatory function", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 284, no. 12, 20 March 2009 (2009-03-20), pages 7977 - 7985, XP002575465, ISSN: 0021-9258, [retrieved on 20090120], DOI: 10.1074/JBC.M808620200 *
JÜRGEN BERNHAGEN ET AL: "MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 13, no. 5, 5 March 2007 (2007-03-05), pages 587 - 596, XP008140753, ISSN: 1078-8956, DOI: 10.1038/NM1567 *
VERA PEDRO L ET AL: "Cyclophosphamide-Induced Cystitis Increases Bladder CXCR4 Expression and CXCR4-Macrophage Migration Inhibitory Factor Association", PLOS ONE, vol. 3, no. 12, December 2008 (2008-12-01), XP002699221, ISSN: 1932-6203 *
WEBER CHRISTIAN ET AL: "Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, no. 42, October 2008 (2008-10-01), pages 16278 - 16283, XP002699220, ISSN: 0027-8424 *
WEBER ET AL: "Abstract: 559 CHEMOKINES AS THERAPEUTIC TARGETS IN ATHEROSCLEROSIS", ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER, AMSTERDAM, NL, vol. 10, no. 2, 1 June 2009 (2009-06-01), pages e1684 - e1685, XP026781902, ISSN: 1567-5688, [retrieved on 20090601], DOI: 10.1016/S1567-5688(09)71632-0 *

Also Published As

Publication number Publication date
AU2010298249A1 (en) 2012-04-19
BR112012006468A2 (en) 2016-08-09
KR20120105429A (en) 2012-09-25
CA2773978A1 (en) 2011-03-31
CN102725311A (en) 2012-10-10
WO2011038149A3 (en) 2011-10-27
WO2011038149A2 (en) 2011-03-31
IN2012DN02423A (en) 2015-08-21
MX2012003514A (en) 2012-04-19
EP2480579A2 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
IL207752A0 (en) Methods of treating inflammation
EP2331564A4 (en) Methods of treating inflammation
EP2585075A4 (en) Methods of treatment for esophageal inflammation
HK1217763A1 (en) Methods of treating diseases
ZA201304280B (en) Treatment of jak2-mediated conditions
IL208354A0 (en) Methods of treatment
EP2480579A4 (en) Methods of treating inflammation
GB0915515D0 (en) Treatment of vasculoproliferative conditions
IL214664A0 (en) Methods of treating hair related conditions
HK1166305A1 (en) Compositions and methods for the treatment of inflammation
GB201018147D0 (en) Method of treatment
IL206491A0 (en) Treatment of produce
IL256026B (en) Methods of treatment
GB201003920D0 (en) Method of treatment
DK2473482T3 (en) Methods of treating orthomyxoviral infections
GB0901456D0 (en) Treatment of psoriasis
IL218230A0 (en) Method of treating cancer
GB201012926D0 (en) Compounds for treatment of inflammation
IL200753A0 (en) Treatment of psoriasis
GB0908101D0 (en) Treatment of stress
EP2585103A4 (en) Method of treatment
GB201018149D0 (en) Method of treatment
EP2440238A4 (en) Methods of treatment
GB201020015D0 (en) Method of treatment
IL216629A0 (en) Methods of treating inflammation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120314

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DURON, SERGIO

Inventor name: WEBER, CHRISTIAN

Inventor name: SCHULTZ, JOSHUA, ROBERT

Inventor name: TURNER, COURT

Inventor name: VOLLRATH, BENEDIKT

Inventor name: BERNHAGEN, JURGEN

Inventor name: ZERNECKE, ALMA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130702

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 19/00 20060101AFI20130624BHEP

Ipc: A61P 35/00 20060101ALI20130624BHEP

Ipc: C07K 14/435 20060101ALI20130624BHEP

Ipc: C07K 7/06 20060101ALI20130624BHEP

Ipc: C07K 7/08 20060101ALI20130624BHEP

Ipc: A61K 38/18 20060101ALI20130624BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140130